Albumin-based NPs have shown significant potential in delivering anticancer drugs to tumour sites, enhancing drug accumulation, and overcoming drug resistance. Four albumin-based nanomedicines, all of which are prepared by Nab-technology, have been tested in clinical trials for potential use as cancer therapeutics. Abraxane ® (ABI-007), also known as nab-paclitaxel, represents a significant milestone as the first albumin-based drug approved for the treatment of metastatic breast cancer by the FDA in 2005.( ), Its indications expanded to include non-small cell lung cancer and metastatic pancreatic cancer.( ) Abraxane ® takes advantage of albumin's natural properties to enhance the delivery of paclitaxel, which is otherwise hindered by its poor water solubility, facilitating higher dosage administrations within shorter periods. Despite certain dose-limiting adverse effects, clinical trials highlighted Abraxane ® superior performance compared to traditional paclitaxel treatments, evidenced by higher response rates, longer times to tumour progression, and increased median survival rates in breast cancer patients. Abraxane ® also demonstrated significant therapeutic effects in combination with other treatments, such as trastuzumab, bevacizumab, carboplatin, 5-fluorouracil, or gemcitabine. (24) Fyarro ® (nab™ rapamycin) is another Nab-technology albumin nanoparticles that was approved by FDA in 2021 for Advanced malignant PEComa. Other anticancer loaded Nab-technology albumin NPs that are still undergoing clinical trials include ABI-008 (nab-docetaxel) and ABI-011 (nab-thiocolchicine dimer). The clinical application and stage of these therapeutic agents are summarised in Table .